title: Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems.
abstract: An emerging strategy in the treatment of viral infections is the use of antisense DNA or RNA to pair with, and block expression of viral transcripts. RNA, in addition to being an informational molecule, can also possess enzymatic activity. Thus, by combining anti-sense and enzymatic functions into a single transcript, it is now possible to design catalytic RNAs, or ribozymes, which can specifically pair with virtually any viral RNA, and cleave the phosphodiester backbone at a specified location, thereby functionally inactivating the viral RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. There are several different catalytic motifs which possess enzymatic activity, and each one of these can be incorporated into an enzymatic antisense with site-specific cleavage capabilities. By focusing on one type of catalytic motif, the hammerhead, we describe the principles behind the development of ribozymes as transacting, site-specific ribonucleases, several applications of ribozymes in functional destruction of target RNAs, as well as several of the problems confronting their use. We also describe a liposome delivery system which facilitates intracellular inclusion of ribozymes, and may provide a means for therapeutic delivery of ribozymes to HIV-1 infected cells.
authors.affiliation: Department of Molecular Genetics, Beckman Research Institute of the City of Hope, Duarte, CA 91010.
authors.forename: J J
authors.initials: JJ
authors.lastname: Rossi
authors.forename: D
authors.initials: D
authors.lastname: Elkins
authors.forename: J A
authors.initials: JA
authors.lastname: Zaia
authors.forename: S
authors.initials: S
authors.lastname: Sullivan
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001483:Base Sequence; D004337:Drug Carriers; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008081:Liposomes; D008969:Molecular Sequence Data; D016337:RNA, Catalytic / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000998:Antiviral Agents; D004337:Drug Carriers; D008081:Liposomes; D016337:RNA, Catalytic